On November 3, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), reported four preclinical research presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations cover BriaCell’s personalized off-the-shelf immunotherapy platform, Bria-OTS+, and three BriaPro research programs: BP-80, a soluble CD80-Fc fusion protein; TILsRx-001, a tumor-targeted CD80-based checkpoint inhibitor; and engineered CD80 variants with altered immune receptor binding.
"The Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing in laboratory models spanning breast, prostate and lung cancers," said Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. "These findings support continued investigation of the platform, including how its immune responses may translate into clinical activity, potentially providing more durable and effective cancer immunotherapies."
"The four presentations provide additional preclinical data supporting our cellular and protein-based immunotherapy research," stated William V. Williams, MD, BriaCell’s President and CEO. "We are advancing the clinical evaluation of our Bria-OTS+ programs while continuing preclinical development of BriaPro’s candidates."
Presentation abstract summaries are listed below.
BriaCell
Title: A Multifaceted Genetically Engineered Whole-Cell Vaccine Platform Generates Potent, Broad, Persistent, and Effector-Centric Anti-Tumor Immunity Across Multiple Cancer Indications
Abstract Number: 863
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026
Summary: Bria-OTS+ is a modular allogeneic whole-cell vaccine platform engineered to combine tumor-derived antigens, immune-stimulatory cytokines, co-stimulatory molecules, and diverse HLA antigens. Bria-OTS+ activated innate and adaptive immune cells, including dendritic, NK, NKT, CD4+ T, and CD8+ T cells, represented by increased activation markers, cytokine production, proliferation, and cytotoxicity. Bria-OTS+ also induced immune activation in PBMCs obtained from cancer patients, extending these findings beyond healthy-donor models.
In vitro studies showed that Bria-OTS+ stimulated innate and adaptive immune responses, broad tumor recognition, sustained cytotoxicity, and memory-like responses across breast, prostate, and lung cancer models, supporting its potential as a broadly applicable cancer immunotherapy platform.
BriaPro
Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
Abstract Number: 404
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026
Summary: BP-80 is a soluble CD80-Fc fusion protein incorporating the full wild-type CD80 extracellular domain, designed to promote T cell activation through CD28 co-stimulation and counteracting CTLA-4-mediated inhibition. Its Fc region contains L234A/L235A (LALA) mutations to reduce antibody-dependent effector functions. In cell-based assays, BP-80 demonstrated CD28 co-stimulatory activity and counteracted CTLA-4-mediated inhibition, with activity dependent on Fc receptor engagement and anti-Fc antibody-based crosslinking, respectively. In cynomolgus monkeys, BP-80 demonstrated a no observed effect level (NOEL) of 50 mg/kg/day and a half-life ranging from 8.08 to 8.92 hours.
Title: Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes
Abstract Number: 405
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026
Summary: TILsRx-001 is a tumor-targeted, tetravalent immune checkpoint inhibitor comprising an engineered CD80 extracellular domain with enhanced PD-L1 affinity and an anti-B7-H3 single-chain variable fragment (scFv) for tumor targeting. In a cell-based study, TILsRx-001 antagonized the immune inhibitory effect of PD-L1 expressed on cells co-expressing B7-H3, supporting further investigation of targeted checkpoint inhibition to enhance tumor-infiltrating lymphocyte (TIL) activity.
Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28
Abstract Number: 406
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026
Summary: CD80 (B7-1) regulates T cell activity through interactions with CD28, PD-L1, and CTLA-4. Structure-guided protein engineering identified CD80 variants with increased PD-L1 binding affinity and minimal effect on CD28 affinity, a potential approach to limiting excessive T cell stimulation. One variant demonstrated more than 130-fold stronger PD-L1 binding than wild-type CD80 (0.23 µM versus >30 µM). Another mutation increased CTLA-4 affinity approximately fivefold while preserving CD28 affinity. These findings support further development of engineered CD80 proteins for cancer immunotherapy.
(Press release, BriaCell Therapeutics, NOV 3, 2026, View Source [SID1234674130])